Skip to main content

Table 1 Clinical data of 50 PCa patients analyzed by IHC using conventional paraffin slides with regard to TET1 expression (n = 50 patients in total)

From: Tracing TET1 expression in prostate cancer: discovery of malignant cells with a distinct oncogenic signature

  Count (%) Age (y) PSA (ng/mL)
Median Range Median Range
T2a–c 26 (52.0%) 64.24 47.8–75.1 7.0 0.1–54.8
T3a–b 24 (48.0%) 64.16 55.5–74.9 9.0 0.6–27.2
GS6 23 (46.0%) 65.88 47.8–75.1 8.8 0.1–24.8
GS7 20 (40.0%) 63.93 54.8–73.1 8.8 0.8–54.8
GS8 2 (4.0%) 65.53 58.2–72.8 6.0 2.7–9.3
GS9 5 (10.0%) 65.20 55.5–74.9 14.1 6–22.1
  1. PCa prostate cancer, ICH immunohistochemical analysis, TET1 ten–eleven translocation family member 1, y years, PSA prostate-specific antigen, T tumor stage, GS Gleason score